Tumor blood vessels supply oxygen and nutrients to cancer cells and provide access to other organs. While tumor vasculature shares many features with normal vessels, their unique characteristics are potential therapeutic targets. A recent study in the Journal of Clinical Investigation identifies a tumor vessel-specific protein, L1 that can be targeted to reduce tumor growth. Using a mouse pancreatic cancer model, Ugo Cavallaro and colleagues at the European Institute of Oncology found that loss of L1 reduced tumor blood vessel formation, which inhibited growth and metastasis. In patients with pancreatic cancer, L1 was present within tumor blood vessels and not in vessels of healthy tissue. The results from this study suggest that targeting L1 has potential as a cancer-limiting strategy.
TITLE:
Endothelial deficiency of the adhesion molecule L1 reduces tumor angiogenesis and promotes vessel normalization
AUTHOR CONTACT:
Ugo Cavallaro
IEO - European Institute of Oncology, Milano, ITA
Phone: +39 02 9437 5165; E-mail: ugo.cavallaro@ieo.eu
View this article at: http://www.jci.org/articles/view/70683?key=566e124081c620ff2944
Journal
Journal of Clinical Investigation